

August 31, 2021

Acurx Pharmaceuticals

Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Investors may listen to the presentation online beginning on September 13 at 7:00 A.M. (ET) via the link below.

Event:	H.C. Wainwright 23 rd Annual Global Investment Conference
Date:	September 13-15, 2021
Session Start Date and Time:	7 a.m. ET on September 13, 2021
Webcast:	https://journey.ct.events/view/75943fdc-2093-4e66-a80a-c6d6e6f9ed6a
Archived:	90 days

About Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase III C enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including *Clostridioides difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant *Streptococcus pneumoniae* (DRSP).

To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.

Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other factors. In addition, the forward-looking statements

included in this press release represent our views as of August 30, 2021. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward- looking statements at some point in the future, we specifically disclaim any obligation to do so.

Investor Contact:

Acurx Pharmaceuticals, Inc.

David P. Luci, President & CEO

Tel: 917-533-1469

Email: davidluci@acurxpharma.com

 View original content: <https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-2021-301365066.html>

SOURCE Acurx Pharmaceuticals, Inc.